MARKET

MNOV

MNOV

MediciNova Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

7.85
+0.14
+1.82%
After Hours: 7.85 0 0.00% 16:00 11/15 EST
OPEN
7.79
PREV CLOSE
7.71
HIGH
7.97
LOW
7.79
VOLUME
71.31K
TURNOVER
--
52 WEEK HIGH
13.37
52 WEEK LOW
6.68
MARKET CAP
344.16M
P/E (TTM)
-30.1228
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of MNOV and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 2 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

MNOV News

  • Here is What Hedge Funds Think About MediciNova, Inc. (MNOV)
  • Insider Monkey.11/06 18:50
  • MNOV: Phase 3 Trial Initiated for MN-166 in ALS
  • Zacks Small Cap Research.10/31 00:00
  • MediciNova nabs new Canadian patent covering ibudilast
  • seekingalpha.10/28 15:45
  • MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Treatment of Amyotrophic Lateral Sclerosis (ALS) in Canada
  • GlobeNewswire.10/28 11:00

More

Industry

Biotechnology & Medical Research
+1.49%
Pharmaceuticals & Medical Research
+1.29%

Hot Stocks

Name
Price
%Change

About MNOV

Medicinova, Inc. is a biopharmaceutical company. The Company focuses on acquiring and developing small molecule therapeutics for the treatment of diseases with unmet medical needs and a commercial focus on the United States market. Its pipeline includes MN-166 (ibudilast), MN-001 (tipelukast), MN-221 (bedoradrine) and MN-029 (denibulin). MN-166 is an oral, anti-inflammatory and neuroprotective agent. MN-166 is in development for the treatment of several neurological diseases, such as progressive multiple sclerosis, amyotrophic lateral sclerosis, and substance dependence and addiction. MN-001 (tipelukast) is an orally bioavailable small molecule compound, which is used for the treatment of fibrotic diseases, such as nonalcoholic steatohepatitis and idiopathic pulmonary fibrosis. MN-221 treats acute exacerbations of asthma through intravenous infusion, bypassing constricted airways to deliver the drug to the lungs. MN-029 is used for the treatment of solid tumor cancers.
More

Webull offers MediciNova, Inc. (MNOV) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.